Interventions in Hypertrophic Obstructive Cardiomyopathy

Wern Yew Ding1, Mohammed N Meah2, Rodney Stables2

  • 1Liverpool Heart and Chest Hospital, Liverpool, United Kingdom; Liverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool, United Kingdom.

PubMed

Insights

Obstructive hypertrophic cardiomyopathy (oHCM) management is complex. This review details current and emerging percutaneous and surgical treatments for oHCM patients, aiming to clarify therapeutic options.

Area of Science:

  • Cardiology
  • Genetics
  • Interventional Cardiology

Background:

  • Obstructive hypertrophic cardiomyopathy (oHCM) is the most common inherited cardiomyopathy.
  • oHCM leads to substantial morbidity and mortality.
  • Current oHCM management strategies are not well-defined compared to other cardiac conditions.

Purpose of the Study:

  • To review established and novel therapeutic interventions for obstructive hypertrophic cardiomyopathy.
  • To focus on percutaneous and surgical treatment modalities for oHCM.

Main Methods:

  • Literature review of established and novel interventions for oHCM.
  • Discussion of surgical myectomy, mitral valve procedures, and percutaneous septal ablation.
  • Exploration of device-based therapies and catheter ablation techniques.

Main Results:

  • Surgical myectomy and mitral valve interventions are key surgical options.
  • Percutaneous alcohol septal ablation and septal embolization are discussed.
  • Radiofrequency ablation techniques, including percutaneous intramyocardial septal ablation, are reviewed.

Conclusions:

  • A comprehensive range of percutaneous and surgical options exist for oHCM.
  • Further research is needed to refine management guidelines for oHCM.
  • Optimizing treatment strategies is crucial for improving outcomes in oHCM patients.

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
341
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
594
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
395
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
174